Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to date

Abstract excerpt

INTRODUCTION: Nearly two decades after leucine rich repeat kinase 2 (LRRK2) was discovered as a genetic determinant of Parkinson's disease (PD), LRRK2 has emerged a priority therapeutic target in PD and inhibition of its activity is hypothesized to be beneficial. AREAS COVERED: LRRK2 targeting agents, in particular kinase inhibitors and agents reducing LRRK2 expression show promise in model systems and have...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Metabolism, Diabetes, and Cancer
• Share to Parkinson's Disease and Spinal Disorders
• Share to Parkinson's Disease Mechanisms and Treatments